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Abstract
Background: The mechanism of rapid growth of the residual tumor after radiofrequency (RF) ablation is poorly understood.
In this study, we investigated the effect of hyperthermia on HepG2 cells and generated a subline with enhanced viability
and dys-regulated angiogenesis in vivo, which was used as a model to further determine the molecular mechanism of the
rapid growth of residual HCC after RF ablation.
Methodology/Principal Findings: Heat treatment was used to establish sublines of HepG2 cells. A subline (HepG2 k) with a
relatively higher viability and significant heat tolerance was selected. The cellular protein levels of VEGFA, HIF-1a and p-Akt,
VEGFA mRNA and secreted VEGFA were measured, and all of these were up-regulated in this subline compared to parental
HepG2 cells. HIF-1a inhibitor YC-1 and VEGFA siRNA inhibited the high viability of the subline. The conditioned media from
the subline exerted stronger pro-angiogenic effects. Bevacizumab, VEGFA siRNA and YC-1 inhibited proangiogenic effects of
the conditioned media of HepG2 k cells and abolished the difference between parental HepG2 cells and HepG2 k cells. For
in vivo studies, a nude mouse model was used, and the efficacy of bavacizumab was determined. HepG2 k tumor had
stronger pro-angiogenic effects than parental HepG2 tumor. Bevacizumab could inhibit the tumor growth and
angiogenesis, and also eliminate the difference in tumor growth and angiogenesis between parental HepG2 tumor and
HepG2 k tumor in vivo.
Conclusions/Significance: The angiogenesis induced by HIF1a/VEGFA produced by altered cells after hyperthermia
treatment may play an important role in the rapid growth of residual HCC after RF ablation. Bevacizumab may be a good
candidate drug for preventing and treating the process.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and the third most common cause of cancer
mortality [1]. Although hepatic resection and transplantation have
been considered as the main curative therapies for HCC, the
advanced neoplastic stage, severity of liver diseases or shortage of
donors limit their application [2]. Recently, Loco-regional
treatments play a key role in the management of HCC [3],
especially radiofrequency (RF) ablation because of its definitive
therapeutic effect, minimal invasiveness, repeatability and safety
[2]. RF ablation heats tissues by ionic friction from RF current,
which induces coagulation necrosis once tissue temperature
exceeds 50uC for 4–6 minutes [3].
However, more and more clinical cases about rapid growth of
residual HCC after RF ablation have been reported since 2001
[4–7]. RF ablation of colorectal liver metastases promotes
proliferation of residual intra-hepatic neoplastic cells [8–11].
Our previous research also demonstrated that low temperature
of RF ablation at the target sites could facilitate rapid progression
of residual hepatic VX2 carcinoma [12]. Cumulative evidence has
demonstrated that residual tumor after RF ablation might exhibit
an aggressive phenotype and unfavorable prognosis, and even
change to sarcoma, which leads to the deterioration of patient’s
condition [12]. However, the mechanisms of rapid growth of
residual HCC after RF ablation or the mediators which play a key
role in the rapid growth are still poorly understood.
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Figure 1. The viability of HepG2 cells and sublines derived from HepG2 cells after hyperthermia. (A) HepG2 cells were cultured after
47uC heat treatment. The 24 h, 48 h and 72 h cell viability of HepG2 cells with or without 47uC heat treatment were measured using MTT assay. (B)
Twenty-four sublines were established after 47uC heat treatment for 10 min as described in the method. The 24 h, 48 h, and 72 h viability was
evaluated by MTT assay after 24 sublines were established. par, parental HepG2 cells; a–x, sublines derived from the HepG2 cells. (C) The 24 h, 48 h
and 72 h viability of representative sublines of HepG2 cells were evaluated by MTT assay. (D) Parental HepG2 and HepG2 k cells were treated with
49uC or 50uC 10 min. The 4 h, 12 h, 24 h and 48 h cell viability were measured by MTT assay. *, P,0.05; **, P,0.01; ***, P ,0.001. Data are the
representative results of three independent experiments. The coefficients of variation (CV) of all assays were shown in Supporting Information S1.
doi:10.1371/journal.pone.0037266.g001
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Hypoxia inducible factor-1 alpha (HIF-1a), a master regulator
of essential adaptive responses to hypoxia, is highly expressed in
hypoxic conditions and maintains a low concentration in
normoxic condition [13]. HIF-1a is generally more pronounced
in aggressive tumors [14] and can be an independent predictor of
poor prognosis in HCC [15]. HIF-1a plays a major role in the
development of a characteristic tumor phenotype influencing
growth rate, angiogenesis, invasiveness, and metastasis [16].
Angiogenesis, which plays a critical role in tumor formation and
maintenance [17], is the most significant because it is essential for
the other biological characteristics [18]. A great number of
angiogenesis associated genes are directly induced by HIF-1a,
such as NOS (nitric oxide synthases), angiogenic and vascular
growth factors (VEGF) and urokinasetype plasminogen activator
receptor (uPAR). Vascular endothelial growth factor (VEGF)
family, of structurally related molecules including VEGFA,
VEGFB, VEGFC, VEGFD and placental growth factor (PLGF),
is one of the most potent angiogenic factors expressed in various
human cancers [19]. Studies have shown that VEGF is frequently
expressed in HCC [20]. The expression of VEGF in HCC tissue
or serum indicates the vascular invasion and metastasis of HCC,
reduced median survival, and the recurrence of HCC after
treatments [21–30]. Bevacizumab, a humanized monoclonal
antibody directed against VEGFA ligand to prevent endothelial
cell receptor activation, was the first anti-angiogenesis agent to
attain approval from the United States Food and Drug Admin-
istration (FDA) [31]. Bevacizumab has been used not only in
colorectal cancer, lung cancer, breast cancer, glioblastoma and
renal cell carcinoma, but also in HCC [31–33]. However, whether
Figure 2. HepG2 k cells express elevated level of VEGFA. (A) Expression of p-Akt, HIF-1a and VEGFA in parental HepG2 and HepG2 k cells were
detected by western blot analysis. (B) The mRNA expression of VEGFA in parental HepG2 and HepG2 k cells was assayed using real time PCR.
*, P,0.05. (C) VEGFA concentration in conditioned media from parental HepG2 and HepG2 k cells was measured by ELISA analysis. **, P,0.01. (D) The
expression of HIF-1a and VEGFA in parental HepG2 and HepG2 k cells treated with or without LY294002 (20 mM) for 24 h were analyzed by western
blot analysis. (E) VEGFA concentration in conditioned media was detected by ELISA analysis. ***, P,0.001 versus parental HepG2 cells control
respectively; ###, P,0.001 versus HepG2 k cells; ns, no significance.
doi:10.1371/journal.pone.0037266.g002
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bevacizumab can be used routinely to prevent the rapid growth of
residual HCC after RF ablation is still not clear.
We hypothesized that insufficient RF ablation could promote
proliferation and angiogenesis of residual HCC, which played a
key role in the rapid growth of residual HCC after RF ablation. In
this study, we sought to determine whether hyperthermia could
directly generate a subline of HepG2 cells with the rapid
proliferation and enhanced pro-angiogenic effect through a HIF-
1a/VEGFA dependent mechanism.
Materials and Methods
Ethics Statement
The animal experiments were approved by the Animal Care
Committee of Capital Medical University, Beijing, China and
were performed in accordance with the institutional guideline.
Materials
The PI3K/Akt inhibitor LY294002, the HIF-1a inhibitor YC-
1, 3-(50-hydroxy methyl-20-furyl)-1-benzylindazole and MTT, 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide were
purchased from Sigma-Aldrich (St. Louis, MO). Bevacizumab was
purchased from Roche (Shanghai, China). Lipofectamine RNAi-
MIX reagent was obtained from Invitrogen (Carlsbad, CA).
Antibodies used in the present study include the following: The
rabbit polyclonal anti-CD34, anti-VEGFA and anti-b-actin
antibodies were purchased from Boster (Wuhan, China). The
rabbit monoclonal anti-phospho-Akt antibody was provided by
Cell Signaling Technology (Danvers, MA). The anti-Akt antibody
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
HRP-goat-anti-rabbit IgG and HRP-goat-anti-mouse IgG were
purchased from MBL (Nagoya, Japan).
Cell lines and cell culture
HepG2 cells, a human hepatoma cell line, was brought from
Cell Resource Center, Chinese Academy of Medical Sciences,
Peking Union Medical College, and cultured in Dulbecco’s
modified Eagle’s with high glucose supplement (DMEM, GIBCO,
UK) containing 10% fetal bovine serum (FBS) in a humidified
incubator at 37uC with an atmosphere of 5% CO2. Human
umbilical vein endothelial cells (HUVECs) were isolated by
Figure 3. YC-1 and VEGFA siRNA inhibit HepG2 cell viability. The parental HepG2 and HepG2 k cells were treated with or without YC-1(5 mM)
or transfected with or without VEGFA siRNA. (A) The expression of HIF-1a and VEGFA was detected by western blot analysis. (B) VEGFA concentration
in conditioned media was detected by ELISA analysis. **, P,0.01, ***, P,0.001 versus parental HepG2 cells control respectively; ###, P,0.001 versus
HepG2 k cells. (C) Parental HepG2 and HepG2 k cells were transfected with or without VEGFA siRNA for 24 h, 48 h, and 72 h, cell viability was
measured by MTT assay. ***, P,0.01; ns, no significance. (D) Parental HepG2 and HepG2 k cells were treated with or without YC-1 (5 mM) for 24 h,
48 h, and 72 h, cell viability was measured by MTT assay. ***, P,0.001; ns, no significance.
doi:10.1371/journal.pone.0037266.g003
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collagenase digestion of umbilical veins from fresh cords. The cells
were plated on gelatin-coated culture dishes in Endothelial Cell
Medium(ECM; Science, USA) consisting of 500 ml of basal
medium, 25 ml of fetal bovine serum, 5 ml of endothelial cell
growth supplement and 5 ml of penicillin and streptomycin
solution and then cultured in a humidified incubator at 37uC with
an atmosphere of 5% CO2. HUVECs were used at passages 2–5.
Heat treatment of HepG2 cells and establishment of
sublines
The sublines of HepG2 cells after heat treatment were
established as described previously [34]. HepG2 cells were seeded
into the 96-well plate. And after 24 h of incubation, in some
experiments, the plates were sealed and submerged in a water bath
set to 47uC for 10 min. Thereafter, the plates were maintained in
the incubator at 37uC with an atmosphere of 5% CO2. The 24 h,
48 h and 72 h cell viability with or without heat treatment was
measured by MTT assay. To establish the sublines, cells were
cultured in the 24-well plate for the above heat treatment. Then
cells were cultured until subconfluent and passaged sequentially
into the 6-well plate and the 10 cm dish. After two passages in the
10 cm dish, these cells were used as 24 sublines.
MTT assay
The cell viability was evaluated by MTT assays. Cells were
seeded at a concentration of 26103/well in 96-well plates. MTT
solution was added to each well at final concentration of 0.5 mg/
ml and incubated for 4 h. At the end of incubation, formazan
crystals resulting from MTT reduction were dissolved by addition
of 150 ml dimethyl sulfoxide (DMSO) per well. The optical density
was read at 570 nm with a plate reader (model 550, BioRad,
USA). The average values were determined from different wells of
the representative assay.
Heat sensitivities of parental HepG2 and HepG2 k cells
Parental HepG2 and HepG2 k cells were seeded at a
concentration of 56103/well in 96-well plates. After 12 h of
incubation, parental HepG2 and HepG2 k cells were treated by
49uC or 50uC for 10 min. The 4 h, 12 h, 24 h and 48 h cell
viability were measured by MTT assay as described above.
Western blot
Cells were lysed using cell lysis buffer (150 mM NaCl, 50 mM
Tris-HCl, pH 8.0, 0.1% SDS, 1% Triton X-100) containing
protease inhibitors. Equivalent amounts of whole cell extracts were
subjected to SDS-PAGE gel and transferred to nitrocellulose
membranes. The membranes were blocked with 5% non-fat milk
for 2 h and then incubated with respective primary antibody for
5 h followed by the incubation of the appropriate HRP-
conjugated secondary antibody for 2 h at room temperature.
Blots were visualized with an ECL detection kit (Pierce, USA) and
analyzed using Quantity One 1-D Analysis Software (Bio-Rad,
CA).
Real-time PCR assay for VEGFA
Real-time PCR was performed to determine mRNA level of
VEGFA. Total mRNA was extracted using the TRIzol reagent
(Invitrogen, USA) and reverse transcription was performed using
an RT-PCR kit (TransGen Biotech, China). Real-time experi-
ments were conducted on a DNA Engine Opticon System (MJ
research Inc, USA) using SYBR Green PCR Master Mix kit in
triplicate specific primers. The sequences of primers to determine
the expression of the target gene were listed as follows: VEGFA
[59-TTCAAGCCATCCTGTGC-39 (forward); 59-TGCTCTA-
TCTTTCTTTGGTCTGC-39 (reverse)] and Glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) [59-CGGAGTCAACGGA-
TTTGGTCGTAT-39 (forward); 59-AGCCTTCTCCATGGTG-
GTGAAGAC-39 (reverse)]. The PCRs consisted of 5 min at 95uC
followed by 40 cycles of denaturation for 30 s at 95uC, annealing
for 30 s at 56uC and a primer extension for 30 s at 72uC. The
comparative CT method was used to quantitate the expression of
VEGFA using GAPDH as the normalized control.
siRNA Knockdown of VEGFA
The VEGFA siRNA and scramble siRNA [scramble siRNA
sequence: sense strand (59-UUCUCCGAACGUGUCACGUTT-
39) and antisense strand: (59-ACGUGACACGUUCGGA-
GAATT-39); VEGFA siRNA sequence: sense strand (59-
CCGAAACCAUGAACUUUCUTT-39) and antisense strand:
(59-AGAAAGUUCAUGGUUUCGGTT-39)] were synthesized
by Shanghai GenePharma Co (Shanghai, China). HepG2 cells
were plated into 6-well plates and allowed to grow to sub-
confluent. Cells were transiently transfected with the siRNA with
lipofectamine RNAiMIX reagent (Invitrogen, Carlsbad, CA) in
OPTI-MEM medium (Gibco) for 12 h, and then incubated and
used for further experiments.
Collection of the conditioned medium
HepG2 cells were transiently transfected with the VEGFA
siRNA or scramble siRNA, or treated with YC-1 (5 mM) or vehicle
for 12 h, and then incubated in DMEM with 0.1% BSA for 14 h
followed by collection of the conditioned medium. The medium
was spun down at 3000 rpm, 20 min, and the supernatant was
collected and stored at280uC. In the experiments of bevacizumab
blocking assay, bevacizumab and control IgG (final, 0.5 mg/ml)
were added into conditioned media 30 min before further
experiment.
Quantification of VEGFA in the conditioned media
VEGFA concentrations in the conditioned media were quan-
tified using an enzyme-linked immunosorbent assay (ELISA) kit
(Dakewe Biotech, China) according to the manufacture’s instruc-
Figure 4. The enhanced pro-angiogenic ability of HepG2 k is in a HIF-1a/VEGFA dependent manner in vitro. (A) HUVECs were treated
with conditioned media from parental HepG2 or HepG2 k cells with addition of bevacizumab (0.5 mg/ml) or control IgG for 24 h. Cell viability were
quantified by MTT assay. (B–C) HUVEC migration in vitro in response to conditioned media from HepG2 k or parental HepG2 cells with addition of
bevacizumab (0.5 mg/ml) or control IgG was assayed after 12 h. The number of migrated cells was quantified by counting 10 random fields at6100
magnification. (D–E) HUVEC tube formation in response to conditioned media from HepG2 k or parental HepG2 cells with addition of bevacizumab
(0.5 mg/ml) or control IgG after 20 h was assayed. The length of tube was evaluated by counting 10 random fields at6100 magnification. (F–H) The
parental HepG2 and HepG2 k cells were treated with or without VEGFA siRNA or 5 mM YC-1, and the conditioned media was collected. The effect of
various conditioned media on HUVEC 24 h viability was quantified by MTT assay. The effect of various conditioned media on HUVEC migration for
12 h was assayed. The number of migrated cells was quantified by counting 10 random fields at 6100 magnification. The effect of various
conditioned media on HUVEC tube formation for 20 h was assayed. The tube length was evaluated by counting 10 random fields at 6100
magnification. *, P,0.05, ***, P,0.001 versus parental HepG2 cell control; ##, P,0.01, ###, P,0.001 versus HepG2 k cells control; ns, no significance.
doi:10.1371/journal.pone.0037266.g004
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tions. We collected the total cell protein to assess the different cell
numbers of the different group. Equal volume of lysis buffer was
added before we extracted the total cellular protein, then we
performed bicinchoninic acid (BCA) assay to evaluate the protein
concentration. Thereafter, the VEGFA concentration was nor-
malized to the total cellular protein.
Figure 5. Bevacizumab impaired the tumor growth and angiogenesis in tumor-bearing mice in vivo. 26106 HepG2 k or parental HepG2
cells in cells in 200 ml phosphate buffered saline were injected by subcutaneous injection to obtain s. c. tumors. (A) Average tumor volume is shown
for the HepG2 tumors. Parental HepG2 tumor with control IgG (n = 5), Parental HepG2 tumor with Bevacizumab (n = 5), HepG2 k tumor with control
IgG (n = 5) and HepG2 k tumor with Bevacizumab (n = 5). **, P,0.01. (B) Mice were killed after 28 days implantation and the tumor tissues were
removed and weighed. *, P,0.05. (C–D) Twenty-eight days after implantation, the numbers of new microvessels marked with CD34 (arrow heads) in
the subcutaneous tumors were quantified by performing new vessel counts of 10 random fields at6400 magnification. *, P,0.05, **, P,0.01 versus
parental HepG2 tumor respectively; ###, P,0.001 versus HepG2 k tumor. (E) Immunohistochemistry analysis of the expression of VEGF in implanted
tumors.
doi:10.1371/journal.pone.0037266.g005
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Cytotoxicity of bevacizumab on HUVECs
HUVECs (16104/well) were seeded into gelatin-coated 96-well
plates and allowed initially to attach for 24 h. Bevacizumab was
added to the wells at final concentration of 0.5 mg/ml. 24 h cell
viability was performed by MTT assay as described above.
HUVEC viability assays
HUVECs were seeded into gelatin-coated 96-well plates. After
24 h incubation, the ECM was removed and various conditioned
media were added to the wells. HUVEC viability was evaluated by
MTT assay as described above. The relevant effect of conditioned
media was normalized to the total cellular protein.
HUVEC migration assay
Quantitative cell migration assays were performed using a
modified Boyden chamber (Minicell, Millipore, USA) with 8.0-mm
pore polycarbonate filter inserts in 24-well plates as described
before [35]. Briefly, the lower chamber was filled with various
conditioned media. HUVECs (56104 cells/well) in serum-free
medium were added into the upper chamber. The cells were
allowed to migrate for 12 h at 37uC. The non-migrated cells were
removed from the upper surface of the membrane by scraping
with a cotton swab, and the migrated cells were fixed with
methanol, stained with crystal violet, and photographed under an
inverted microscope (Nikon, Japan). Migration was assessed by
counting the number of stained cells from 10 random fields at
6100 magnification. The relevant effect of conditioned media was
normalized to the total cellular protein.
HUVEC tube formation assays
HUVECs (16104/well) resuspended by various conditioned
media were added to Matrigel coated 96-well plates and incubated
at 37uC for 20 h. HUVECs were photographed under an inverted
microscope (Nikon, Japan). Tube formation was assessed by
counting the length of tube from 10 random fields at 6100
magnification. The relevant effect of conditioned media was
normalized to the total cellular protein.
Xenograft assays
Male BALB/c nude mice (5 weeks old) were purchased from
Vital River Laboratories and maintained in the Laboratory
Animal Center of Capital Medical University. 20 mice were
randomized into 4 groups and housed in laminal-flow cabinets
under specific pathogen-free (SPF) conditions. 26106 HepG2 k or
parental HepG2 cells in 200 ml phosphate buffered saline were
implanted by subcutaneous injection to obtain s. c. tumors. After
establishment, tumor-bearing mice were treated with bevacizumab
or control IgG (5 mg/kg i.p. qd) every day. The tumor growth was
monitored by periodic caliper every 3 days, and the tumor volume
was calculated according to the formula tumor volume= (largest
diameter 6 perpendicular2)/2. After 4 weeks, mice were
euthanized and tumor tissues were removed for fixation in the
4% paraformaldehyde solution.
Immunohistochemical analysis
Tumor tissues from mouse model (n = 20) were embedded into
paraffin. Paraffin-embedded tissue sections were cut into standard
6-mm sections, deparaffinaged in xylene and rehydrated through
graded alcohol solutions. Antigen retrieval was performed 10 min
at 93uC in EDTA (10 mmol/l, PH 8.0) in a water bath.
Endogenous peroxidases were inactivated by immersing the
sections in 0.3% hydrogen peroxide for 12 min. The sections
were incubated at 37uC with primary antibodies contained mouse
monoclonal mouse monoclonal anti-VEGF (dilution 1:50) or
rabbit polyclonal anti-CD34 (dilution 1:100) for 2 h in a
humidified chamber, then incubated with the appropriate HRP-
conjugated secondary antibody for 40 min at 37uC. Staining
results were viewed under light microscope (Olympus, Leeds
Precision Instruments) and pictures were taken with an imaging
program.
Statistical analysis
As indicated, Student’s t test or ANOVA test was used for
comparison of two groups or four groups using GraphPad Prism
(GraphPad Software Inc., La Jolla, CA). P,0.05 was set as the
level of statistical significance.
Results
Heat treatment can generate sublines from HepG2 cells
with higher viability
To monitor the potential effect of hyperthermia on the tumor
growth, initially we studied the cell viability at 24 h, 48 h, and
72 h of HepG2 cells after the treatment of 47uC for 10 min. It was
found that the cell viability of HepG2 cells after 47uC heat
treatment significantly decreased compared with no heat treat-
ment due to cell apoptosis and death (P,0.001; Figure 1A). To
examine the cell viability of survived HepG2 cells after heat
treatment, HepG2 cells were cultured in the 24-well plate for 47uC
heat treatment and survived cells were continuously cultured until
24 sublines were generated as described in the method. After 24
sublines were generated, the cell viability of sublines was tested at
24, 48, and 72 hour. It was found that the sublines exhibited
significant difference in cell viability compared with parental
HepG2 cells, especially HepG2 k, showing nearly 18.863.1%
higher (P,0.001; Figure 1B and C). Furthermore, we determined
the difference between parental HepG2 cells and HepG2 k cells in
heat resistance. HepG2 k cells showed significant heat tolerance
compared with parental HepG2 cells after 50uC 10 min treatment
(Figure 1D). Therefore, it appeared that heat treatment could kill
HepG2 cells partially and generate a subline derived from parental
HepG2 cells with higher viability and heat resistance. Then we
selected HepG2 k cells for further studies.
VEGFA expression is up-regulated in HepG2 k cells
involving PI3K/Akt/HIF-1a/VEGFA signaling pathway
We sought to determine the molecular discrepancy between
parental HepG2 cells and HepG2 k cells. Western blot demon-
strated that Akt phosphorylation and protein levels of HIF-1a and
VEGFA were increased in HepG2 k cells compared with parental
HepG2 cells (Figure 2A). The mRNA level of VEGFA in HepG2 k
cells increased 2465.4% compared with parental HepG2 cells
(P,0.05; Figure 2B). The ELISA results showed that 18.262.6%
more VEGFA was secreted from HepG2 k cells than that from
parental HepG2 cells (P,0.01; Figure 2C). Subsequently, we
observed that both specific PI3K/Akt inhibitor LY294002 and
HIF-1a inhibitor YC-1 were able to decrease HIF-1a, VEGFA
expression, and secreted VEGFA in parental HepG2 cells and
HepG2 k cells (Figure 2D,E and 3A,B). Our findings demonstrated
that increased VEGFA expression in HepG2 k cells was regulated
involving the PI3K/Akt/HIF-1a/VEGFA pathway.
YC-1 and VEGFA siRNA inhibit HepG2 cell viability
To investigate the role of HIF-1a and VEGFA in the difference
of cell viability between parental HepG2 cells and HepG2 k cells,
YC-1 and VEGFA siRNA were used. The viability of parental
Insufficient Radiofrequency Ablation/Angiogenesis
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HepG2 cells and HepG2 k cells at 24, 48, and 72 h after YC-1
treatment and VEGFA siRNA transfection was significantly lower
than those of the control group (Figure 3C and D). Meanwhile,
YC-1 treatment or VEGFA siRNA transfection eliminated the
difference of viability between parental HepG2 cells and HepG2 k
cells (Figure 3C and D).
HepG2 k cells promotes angiogenesis through HIF-1a/
VEGFA
We further explored the difference of HepG2 k cells and
parental HepG2 cells in promoting the angiogenesis and the roles
of HIF-1a and VEGFA in that process. It was found that the effect
of the conditioned media (plus control IgG) from HepG2 k cells on
HUVEC viability (Figure 4A), migration (Figure 4B,C), and tube
formation (Figure 4D,E) increased by 36.769.6%, 44.3616.5%
and 33.3611.9% respectively, compared with that from parental
HepG2 cells (all at P,0.001). The addition of bevacizumab
showed no cytotoxicity on HUVECs (Figure S1 in Supporting
Information S1) and blocked the pro-angiogenic effect of the
conditioned media on HUVEC viability, migration and tube
formation (all at P,0.001; Figure 4A–E). In addition, bevacizu-
mab eliminated the significant difference in pro-angiogenic effect
of the conditioned media between HepG2 k cells and parental
HepG2 cells (Figure 4A–E). To further determine the effect of
HIF-1a/VEGFA mechanism in angiogenesis, HIF-1a inhibitor
YC-1 and VEGFA siRNA were used to decrease the expression
and secretion of VEGFA (Figure 3A and B). It was found that
HUVEC viability, migration and tube formation were significantly
inhibited by the conditioned media from HepG2 cells with YC-1
treatment or knockdown of VEGFA (Figure 4F,G and H).
Moreover, YC-1 and VEGFA siRNA eliminated the significant
difference in pro-angiogenic effect of the conditioned media
between HepG2 k cells and parental HepG2 cells (Figure 4F,G
and H).
HepG2 k subline cells have higher tumor growth and
angiogenesis in vivo, and Bevacizumab can inhibit them
To confirm the results in vitro, we examined the growth of the
HepG2 k tumor and parental HepG2 tumor, and the effects of
bevacizumab in vivo. After 28 days of treatment, the group of
HepG2 k tumor with control IgG showed increased tumor volume
in comparison to the group of parental HepG2 tumor with control
IgG (P,0.01); groups with treatment of bevacizumab showed
decreased tumor volume in comparison to groups with treatment
of control IgG (P,0.01); the treatment of bevacizumab signifi-
cantly diminished the difference of the tumor growth between
HepG2 k tumor and parental HepG2 tumor (Figure 5A).
Similarly, the weights of the HepG2 k tumor xenografts are
higher than those of the parental HepG2 tumor, but with no
statistical significance. Additionally, the weights of groups injected
with bevacizumab were markedly decreased in comparison to that
of the groups with control IgG (P,0.05; Figure 5B). Quantifica-
tion of CD34-marked microvessel density (MVD) in tumor
xenograft samples indicated that samples derived from the group
of HepG2 k tumor with control IgG revealed a 59.4640.0%
higher angiogenesis in comparison to the group of parental
HepG2 tumor with control IgG (P,0.05; Figure 5C and D). And
bevacizumab inhibited the angiogenesis of parental HepG2 tumor
and HepG2 k tumor significantly (**, P,0.01; ###, P,0.001;
Figure 5C and D). Immunohistochemistry analysis showed that, in
the groups treated with control IgG, the expression of VEGF in
HepG2 k tumor was higher compared with that in parental
HepG2 tumor. And bevacizumab significantly inhibited the
expression of VEGF in HepG2 k tumor and parental HepG2
tumor (Figure 5E).
Discussion
The phenomenon of rapid growth of residual liver tumor after
RF ablation has been observed in many clinical centers. Our
previous study demonstrated that residual tumor was prone to
proliferation, invasion and metastasis when the local ablative
temperature was not sufficiently high [12]. However, whether the
angiogenesis which may be induced by hyperthermia produced by
RF ablation on HCC cells plays a role in the rapid growth of
residual HCC after RF ablation has remained undetermined.
In vitro we simulated the growth pattern of the hepatoma cells
which were not killed after treatment of hyperthermia generated
by RF ablation. In the study of Obara et al, one of HepG2 sublines
showed more than 100% increase in proliferation, marked heat
tolerance and no obvious difference in invasive capacities
compared with parental HepG2 cells [34]. But the mechanism
of HepG2 with rapid proliferation was not further investigated. In
this study, we found that cell viability of HepG2 cells was inhibited
after the transient heat exposure of 47uC, which was consistent
with the previous study [36], and we also established the sublines
of HepG2 cell which survived the 47uC heat treatment for 10 min.
Among the sublines, HepG2 k cells with the highest viability
showed 18.863.1% increase in viability compared with parental
HepG2 cells. Although the increased percentage of the subline cell
viability in comparison to the parental HepG2 cells was not
corresponding to the previous study, we both revealed that the
hyperthermia can generate a subline with high viability and heat
tolerance. Moreover, cumulative evidence has shown that
suppression of VEGF and HIF-1a inhibited carcinoma cell
proliferation [37–40]. Our further findings demonstrated that
the higher viability of the subline was mediated involving HIF-1a/
VEGFA pathway.
According to Forkman’s reports, the generation of a tumor mass
requires tumor cell proliferation plus angiogenesis. Tumor cell
proliferation alone, in the absence of angiogenesis, can give rise to
dormant, microscopic tumors of ,1 mm3 or less, but these in situ
cancers are harmless to the host [41]. HCC is also a highly
vascular tumor, and the angiogenesis plays a considerable role in
its development and progression [42]. Similarly, our study
revealed that both the pro-angiogenic effect of HepG2 k cells in
vitro and the angiogenesis of HepG2 k tumor in vivo were stronger
than that of parental HepG2 and that of parental HepG2 tumor
respectively.
VEGF, whose most important member is VEGFA, is the most
potent angiogenic factor and plays a key role in tumor associated
angiogenesis and hyper-permeability [19,43,44]. Our previous
study demonstrated that insufficient RF ablation due to low
temperature at the target sites significantly increased the expres-
sion of VEGF of residual VX2 tumor [12]. HIF-1 is a transcription
activator of the VEGF promoter. HIF-1a, a component of HIF-1,
can be induced by hypoxia or mutations of PTEN, VHL,
succinate dehydrogenase (SDH), or fumarate hydratase (FH), as
well as by the activation of ERBB2, SRC, endothelin-1 (ET-1), the
RAS/MARK pathway, and the phosphoinositide 3-kinase (PI3K)-
Akt-mTOR pathway. Moreover, HIF-1a can be stabilized by
reactive oxygen species (ROS) through blocking the PHD activities
[45,46]. Based on these previous researches, we further explored
the underlying molecular mechanism of the enhanced pro-
angiogenic effect of HepG2 k cells in vitro and the angiogenesis
of HepG2 k tumor in vivo. We found that the enhanced Akt
phosphorylation and high protein levels of HIF-1a and VEGFA
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caused the subline to show high viability, which was not reported
previously. Additionally, after we performed HIF-1a inhibitor YC-
1 treatment and VEGFA siRNA transfection to decrease the
VEGFA concentration in the conditioned media, it was found that
the pro-angiogenic effect of the conditioned media was impaired
correspondingly and the difference in pro-angiogenic effect of
HepG2 k and parental HepG2 also diminished. Moreover,
bevacizumab to block the effect of VEGFA in the conditioned
media also showed the similar results. Considering the findings
above, we postulated that the hyperthermia-induced subline
exerted its stronger pro-angiogenic effect through enhanced
PI3K/Akt/HIF-1a/VEGFA signaling pathway. These novel
findings could be a potential mechanism associated with the rapid
growth of the residual tumor after radiofrequency (RF) ablation
and therefore could bear important therapeutic implications.
Anti-VEGF therapies are important in the treatment of certain
cancers. Especially, there have been many studies indicative of the
potential therapeutic benefit of bevacizumab in combination
anticancer therapy [47–51]. However, whether bevacizumab can
be used to control the rapid progression of residual HCC after RF
ablation has not been reported yet. Our study demonstrated that
bevacizumab treatment reduced the pro-angiogenic effect of
conditioned media from HepG2 k cells. Additionally, bevacizu-
mab significantly inhibited the tumor growth and angiogenesis of
HepG2 k tumor in vivo, and bevacizumab eliminated the difference
of tumor growth and angiogenesis between HepG2 k tumor and
parental HepG2 tumor. Therefore, we may provide the support
information of using bevacizumab to prevent the rapid progression
of residual HCC after RF ablation.
Our findings were that hyperthermia induced hepatoma cells to
generate a subline with enhanced PI3K/Akt/HIF-1a/VEGFA
signaling pathway, high viability and dys-regulated pro-angiogenic
effect, which explored the underlying mechanism and potential
therapeutic target of the rapid growth of residual HCC after RF
ablation. Obviously, further researches are needed in the future to
clarify the disease of rapid growth of residual HCC after RF
ablation.
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